This imbalance may drive protein misfolding and promote the accumulation of several disease-associated proteins and underscores the PGRN–GCase–lipid metabolism axis as a promising therapeutic target for multiple neurodegenerative diseases. This evidence concerns the gene GRN and neurodegenerative disease.